Solid Biosciences Inc. SLDB SGT003 — Research And Development Expense
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Solid Biosciences Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Solid Biosciences Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Solid Biosciences Inc.'s sgt003 — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Solid Biosciences Inc.'s SGT003 — research and development expense?
- Solid Biosciences Inc. (SLDB) reported SGT003 — research and development expense of $22.94M in Q1 2026.
- How has Solid Biosciences Inc.'s SGT003 — research and development expense changed year-over-year?
- Solid Biosciences Inc.'s SGT003 — research and development expense increased by 150.3% year-over-year, from $9.17M to $22.94M.
- What is the long-term trend for Solid Biosciences Inc.'s SGT003 — research and development expense?
- Over 2 years (2023 to 2025), Solid Biosciences Inc.'s SGT003 — research and development expense has grown at a 67.3% compound annual growth rate (CAGR), from $20.86M to $58.34M.
- What does SGT003 — research and development expense mean?
- This metric represents the total operating costs directly attributable to the research, clinical development, and manufacturing preparation of the SGT003 gene therapy candidate. It captures the investment intensity required to advance this specific therapeutic asset through preclinical and clinical trial stages. Monitoring this expense provides insight into the company's capital allocation priorities and the pace of development for its core pipeline programs.